Citi Maintains Sell Rating on Hospira
Citi is maintaining its Sell rating on shares of Hospira (NYSE: HSP).
“We maintain our Sell rating, as we remain cautious on increasing competitive pressures along with downside risk to 2012 consensus EPS,” Citi writes. “We leave our 2011 $4.04 EPS estimate unchanged though we lower 2H (offset by 2Q) and lower our 2012/2013 by $0.04 each and remain below Street views beyond 2011.”
Hospira closed Friday at $55.67.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Citi HospiraReiteration Analyst Ratings